Besides shaking, difficulty walking and moving, and rigidity, some members within MyParkinsonsTeam are dealing with hallucinations and delusions. Until April of 2016, the drug treatments developed to address Parkinson's psychosis had the side-effect of contributing to deterioration of motor function. So the question for many diagnosed with Parkinson's psychosis has been: is it better to stay using antipsychotics that further the physical progression of the disease, or better to live with hallucinations in order to preserve motor function for as long as possible?

In April of 2016, Nuplazid by Acadia Pharmacueticals was approved by the FDA for Parkinson's psychosis. The positive research findings behind this drug have been that this is the first antipsychotic to have no impact on motor function. The Parkinson's Foundation has a great summary about the recent findings here.

[April 2018 update: The FDA-approved label for Nuplazid lists common side effects including confused state and peripheral edema (swelling of the legs, feet, or ankles). Rare but serious side effects listed for Nuplazid can include increased risk of death in older adults with dementia. As of April 2018, the FDA is reevaluating the safety of Nuplazid following a number of reported adverse events, including deaths.]

If you are experiencing Parkinson's-related hallucinations or delusions, it may be worth exploring more information about free resources and programs for Nuplazid related to insurance coverage for this drug, financial support, and even home delivery of Nuplazid. Learn more.